Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. (Q50492479)

From Wikidata

Jump to navigation Jump to search

scientific article published on 9 April 2013

Language	Label	Description	Also known as
English	Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.	scientific article published on 9 April 2013

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

phase III clinical trial

0 references

0 references

B-cell lymphoma

1 reference

based on heuristic

inferred from title

diffuse large B-cell lymphoma

1 reference

based on heuristic

inferred from title

Nicolas Mounier

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

René-Olivier Casasnovas

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Thierry J Molina

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Catherine Thieblemont

6

object named as

Catherine Thieblemont

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

16

object named as

Alain Delmer

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Christophe Fermé

12

object named as

Christophe Fermé

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

2

object named as

Hervé Tilly

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Olivier Fitoussi

17

object named as

Olivier Fitoussi

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Richard Delarue

1

object named as

Richard Delarue

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

4

object named as

Tony Petrella

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

7

object named as

Serge Bologna

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Achiel Van Hoof

14

object named as

Achiel Van Hoof

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Christophe Fruchart

10

object named as

Christophe Fruchart

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

9

object named as

Maya Hacini

1 reference

Europe PubMed Central

28 February 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

author name string

Hervé Ghesquières

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Loïc Ysebaert

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Antoine Thyss

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

André Bosly

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

publication date

9 April 2013

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

525-533

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970122-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970122-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-CD20 antibody therapy for B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970122-0

7 January 2021

based on heuristic

inferred from DOI database lookup

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970122-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970122-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970122-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970122-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970122-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970122-0

7 January 2021

based on heuristic

inferred from DOI database lookup

CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970122-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970122-0

7 January 2021

based on heuristic

inferred from DOI database lookup

High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970122-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A resurgence of Pneumocystis in aggressive lymphoma treated with R-CHOP-14: the price of a dose-dense regimen?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970122-0

7 January 2021

based on heuristic

inferred from DOI database lookup

R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970122-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970122-0

7 January 2021

based on heuristic

inferred from DOI database lookup

CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970122-0

7 January 2021

based on heuristic

inferred from DOI database lookup

CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970122-0

7 January 2021

based on heuristic

inferred from DOI database lookup

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970122-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970122-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970122-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970122-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(13)70122-0

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23578722%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50492479&oldid=2120331651"